Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With CHOP, in Patients With Previously Untreated Follicular Lymphoma (FL).

To investigate the efficacy in two dose regimens of ofatumumab in combination with CHOP (cyclophosphamide,doxorubicin, vincristine,prednisolone) in previously untreated patients with Follicular Lymphoma (FL)

Inclusion Criteria:

• Patient with Follicular Lymphoma (FL)
• Confirmed diagnosis of Follicular lymphoma
• 18 years or above
• Verbal and written information about the study

Exclusion Criteria:

• No previous treatment for Follicular Lymphoma
• Clinical suspicion that the Follicular Lymphoma has transformed to aggressive lymphoma
• Several diseases such as malignancies etc.
• Screening laboratory values
• Current participation in any other interventional clinical study
• Breast feeding women or pregnant women
• Women of childbearing potential not willing to use adequate contraception